Colorectal Cancer, Gut Microbiota
Conditions
Keywords
Microbiota, colorectal cancer, relapse, surveillance
Brief summary
Colonic microbiome has been found to contribute to the development of colorectal cancer. We speculate that gut microbiota related to colorectal cancer relapse after curative treatment. This study aim to discover if any difference of gut microbiota exist in patients who suffer from cancer relapse compared with patients who do not. Finally develop patient-centred programmes of surveillance protocols base on microbiota analysis.
Detailed description
Treatments for colorectal cancer of all stages have evolved considerably over the past two decades, resulting in improved long-term outcomes. After curative treatment, however, 30% of patients with stage I-III and up to 65% of patients with stage IV colorectal cancer develop recurrent disease. The human colon plays host to a diverse and metabolically complex community of microorganisms. While the colonic microbiome has been found to contribute to the development of colorectal cancer. Investigators speculate that gut microbiota related to colorectal cancer relapse after curative treatment. Patients are routinely offered surveillance in order to detect disease recurrence at an early, asymptomatic stage, with the intention of improving survival. Nevertheless, controversy continues to surround the optimal surveillance protocols. Investigators aim to discover if any difference of gut microbiota is exist in patients who suffer from relapse compared with patients who do not. Future surveillance after colorectal cancer treatment should focus on risk-stratification and should incorporate current knowledge on risk of recurrence in relation to the biology of the tumour as well as gut microbiota feature. Finally investigators will develop patient-centred programmes of surveillance protocols base on microbiota analysis.
Interventions
None listed
Sponsors
First Affiliated Hospital of Harbin Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
35 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Requirements of informed consent and assent of participant, parent or legal guardian as applicable * Patients with colorectal cancer scheduled for radical coloproctectomy and between the age of 18 and 75 years old without considering sex. * Patients with BMI= 18.5-23.9 * Participants can follow the visit plan
Exclusion criteria
* Patients with colorectal cancer with distant metastasis * Chronic renal diseases and hepatic cirrhosis * Chronic ischemic heart disease with unstable angina, chronic heart failure at class III or IV and acute myocardial infarction in the last 6 months * Individuals with a history of Chronic diarrhea * Individuals with a history of Diabetes mellitus * Individuals with a history of Hypertension * Individuals with a history of autoimmune diseases * Use of antibiotics and probiotics 3 mouth before samples collection * Individuals with a history of abdominal operation due to any reason * Individuals with any history of cancer other than colorectal cancer * Individuals with Inflammatory bowel disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transcriptional changes in gut microbiota | Baseline, 6 months after surgery, 12 months after surgery, 24 months after surgery | 16S rRNA gene sequencing will be performed with stander procedure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Epigenetic changes | Baseline, 6 months after surgery, 12 months after surgery, 24 months after surgery | DNA methylation levels are analysed at baseline and after probiotics use in tissue samples |
Countries
China
Contacts
Primary ContactYunwei Wei
Backup ContactYang Liu
Outcome results
None listed